Genitope Protocol 2000-04

Study 2000-04 is an open-label, single arm Phase 2 study in patients with previously untreated low-grade follicular lymphoma (IWF classification B and C) who do not receive chemotherapy prior to receiving Id immunotherapy. The study is designed to evaluate whether patients still early in the natural history of the disease, or the "watch and wait" period, will mount a specific immune response in the presence of measurable disease.

Approximately six months after biopsy, patients begin a series of five immunizations with Id-KLH and GM-CSF. Patients who demonstrated an Id-specific immune response or a clinical response (at least a 25% reduction in the sum of single product dimensions) were eligible to continue for series of additional three immunizations. The study, conducted at Stanford University Medical Center (Palo Alto, CA), is closed to enrollment. Long-term follow-up is ongoing. Preliminary data was presented at the ASCO 2002 conference.

For questions about Genitope Corporation's clinical trials, please complete and submit the Request Information Form, send email to clinicalinfo@genitope.com, or call our toll-free hotline at 1-866-GENITOP (1-866-436-4867).